125 related articles for article (PubMed ID: 21730268)
1. Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.
Weiss L; Melchardt T; Neureiter D; Kemmerling R; Moshir S; Pleyer L; Greil R; Egle A
J Clin Oncol; 2011 Aug; 29(24):e696-8. PubMed ID: 21730268
[No Abstract] [Full Text] [Related]
2. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone.
Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A
Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
[No Abstract] [Full Text] [Related]
4. Resolution of Waldenström's macroglubulinemia related isolated neutropenia by immunochemotherapy.
van Gelder M; van Marion A; Goossens V; Bommer M; Leblond V
Am J Hematol; 2011 Apr; 86(4):380-2. PubMed ID: 21442645
[No Abstract] [Full Text] [Related]
5. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
[TBL] [Abstract][Full Text] [Related]
6. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
7. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
8. Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia.
Treon SP; Yang G; Hanzis C; Ioakimidis L; Verselis SJ; Fox EA; Xu L; Hunter ZR; Tseng H; Manning RJ; Patterson CJ; Sheehy P; Turnbull B
Br J Haematol; 2011 Jul; 154(2):223-8. PubMed ID: 21564078
[TBL] [Abstract][Full Text] [Related]
9. Durable complete remission after chemotherapy and rituximab in a case of Waldenström's macroglobulinemia with pleuropulmonary involvement.
Capalbo S; Dargenio M; Delia M; Chiefa A; Diomede D; Napoli A; Ricco R; Liso V
Ann Hematol; 2005 Sep; 84(9):625-6. PubMed ID: 15915349
[No Abstract] [Full Text] [Related]
10. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Dreyling M
Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
[No Abstract] [Full Text] [Related]
11. Simultaneous presentation of Waldenström macroglobulinemia and multiple myeloma: multidisciplinary diagnosis, treatment and 30-month follow-up.
Carulli G; Ciancia EM; Azzarà A; Ottaviano V; Grassi S; Ciabatti E; Ferreri MI; Rocco M; Marini A; Petrini M
J Clin Exp Hematop; 2013; 53(1):29-36. PubMed ID: 23801131
[TBL] [Abstract][Full Text] [Related]
12. Waldenström macroglobulinaemia and intestinal lymphangiectasia.
Cooke RE; Kalnins RM; Ho WK
Br J Haematol; 2014 Nov; 167(3):292. PubMed ID: 25039993
[No Abstract] [Full Text] [Related]
13. Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Hivert B; Tamburini J; Vekhoff A; Tournilhac O; Leblond V; Morel P
Haematologica; 2011 May; 96(5):785-8. PubMed ID: 21393333
[No Abstract] [Full Text] [Related]
14. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen.
Treon SP; Hanzis C; Manning RJ; Ioakimidis L; Patterson CJ; Hunter ZR; Sheehy P; Turnbull B
Br J Haematol; 2011 Aug; 154(3):357-62. PubMed ID: 21615385
[TBL] [Abstract][Full Text] [Related]
15. Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.
Laszlo D; Andreola G; Rigacci L; Fabbri A; Rabascio C; Pinto A; Negri M; Martinelli G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):130-2. PubMed ID: 21454213
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
Palombi M; Niscola P; Tendas A; Trawinska MM; Scaramucci L; Giovannini M; Fratoni S; Perrotti A; de Fabritiis P
J Chemother; 2013 Aug; 25(4):247-9. PubMed ID: 23906078
[TBL] [Abstract][Full Text] [Related]
17. Waldeström macroglobulinaemia relapsing with focal bone disease and achieving major response with single-agent zoledronic acid.
Bakhous A; Zhu H; Waheed S
Br J Haematol; 2013 Nov; 163(3):293. PubMed ID: 23930696
[No Abstract] [Full Text] [Related]
18. Fludarabine, cyclophosphamide and rituximab (FCR) induced pulmonary hypertension in Waldenstrom macroglobulinemia.
Lazarevic VLj; Liljeholm M; Forsberg K; Söderberg S; Wahlin A
Leuk Lymphoma; 2008 Jun; 49(6):1209-11. PubMed ID: 18452089
[No Abstract] [Full Text] [Related]
19. Cryoglobulinaemia identified by repeated analytical failure of laboratory tests.
Hira-Kazal R; Sayar Z; Kothari J; Ayrton P; Berney S; Maher J
Lancet; 2014 Jan; 383(9914):382. PubMed ID: 24461124
[No Abstract] [Full Text] [Related]
20. Severe neuropathy in a patient with Waldenstrom disease: from a challenging diagnosis to clinical improvement by innovative therapy.
Bertazzoni P; Andreola G; Laszlo D; Agazzi A; Bassi S; Gigli F; Martinelli G
Leuk Lymphoma; 2006 Sep; 47(9):1970-2. PubMed ID: 17065016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
